Article
 

An inducible kras[superscript v]¹² transgenic zebrafish model for liver tumorigenesis and chemical drug screening

Public Deposited

Downloadable Content

Download PDF
https://ir.library.oregonstate.edu/concern/articles/fx719p014

Descriptions

Attribute NameValues
Creator
Abstract
  • Because Ras signaling is frequently activated by major hepatocellular carcinoma etiological factors, a transgenic zebrafish constitutively expressing the kras(V12) oncogene in the liver was previously generated by our laboratory. Although this model depicted and uncovered the conservation between zebrafish and human liver tumorigenesis, the low tumor incidence and early mortality limit its use for further studies of tumor progression and inhibition. Here, we employed a mifepristone-inducible transgenic system to achieve inducible kras(V12) expression in the liver. The system consisted of two transgenic lines: the liver-driver line had a liver-specific fabp10 promoter to produce the LexPR chimeric transactivator, and the Ras-effector line contained a LexA-binding site to control EGFP-kras(V12) expression. In double-transgenic zebrafish (driver-effector) embryos and adults, we demonstrated mifepristone-inducible EGFP-kras(V12) expression in the liver. Robust and homogeneous liver tumors developed in 100% of double-transgenic fish after 1 month of induction and the tumors progressed from hyperplasia by 1 week post-treatment (wpt) to carcinoma by 4 wpt. Strikingly, liver tumorigenesis was found to be 'addicted' to Ras signaling for tumor maintenance, because mifepristone withdrawal led to tumor regression via cell death in transgenic fish. We further demonstrated the potential use of the transparent EGFP-kras(V12) larvae in inhibitor treatments to suppress Ras-driven liver tumorigenesis by targeting its downstream effectors, including the Raf-MEK-ERK and PI3K-AKT-mTOR pathways. Collectively, this mifepristone-inducible and reversible kras(V12) transgenic system offers a novel model for understanding hepatocarcinogenesis and a high-throughput screening platform for anti-cancer drugs.
  • Keywords: Hepatoblastoma, Gene-expression, Targeted therapies, Hepatocellular-carcinoma, Pathogenesis, Mek inhibitors, In-vivo, Ras, Cancer, Pathway activation
Resource Type
DOI
Date Available
Date Issued
Citation
  • A.T. Nguyen, A. Emelyanov, C.H.V. Koh, J.M. Spitsbergen, S. Parinov, Z. Gong An inducible kras[superscript v]¹² transgenic zebrafish model for liver tumorigenesis and chemical drug screening Disease Models & Mechanisms, 5 (2012), p. 63
Journal Title
Journal Volume
  • 5
Journal Issue/Number
  • 1
Academic Affiliation
Rights Statement
Funding Statement (additional comments about funding)
  • This work was supported by the Biomedical Research Council of Singapore [grant number 07/1/21/19/499].
Publisher
Language
Replaces

Relationships

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details SpitsbergenJanMMicrobiologyInducibleKrasTransgenic.pdf 2017-07-20 Public Download